13th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220096323 | Self-Locking Cover for Drug Waste Management and Systems Implementing Thereof - The present disclosure relates to systems that rely on a self-locking cover to limit access to narcotics. A self-locking cover may allow for a single access opportunity to a narcotics vial, which may be one or both original vials and waste vials. In some aspects, a self-locking cover may be incorporated into narcotics transportation and tracking mechanisms, which may allow for to increased security against tampering or abuse of narcotics, particularly narcotics waste. Self-locking covers may prevent uninhibited and free access to waste narcotics, which may be susceptible to abuse. | 2022-03-31 |
20220096324 | COMMON CONTACT SURFACES FOR USE IN THE MANUFACTURE, PACKAGING, DELIVERY, AND ASSESSMENT OF BIOPHARMACEUTICAL PRODUCTS - System of vessels, connectors, or other equipment characterized by at least some common surfaces in contact with a biopharmaceutical product during biopharmaceutical manufacturing, packaging, delivery, and assessment. Methods of producing those systems and customizing contact surfaces for use in them. | 2022-03-31 |
20220096325 | UNIVERSAL FLUID CONTAINER ENCLOSURE SYSTEMS - Various embodiments are generally directed to fluid container enclosure systems that couple with a fluid container and enable different systems, such as endoscopic systems, to access the contents of the fluid container, such as via a tubing set. The enclosure systems are configured to fit a wide range of fluid container necks, ports, or other openings, including various opening dimensions and thread finishes. In one embodiment, an enclosure system may include a plug having a sleeve extending therefrom. The plug may be deformed manually or via a plunger system to reduce the outer dimension thereof to fit the plug in the neck of a fluid container. Once the plug is arranged within the neck, the sleeve may be folded down over an outer surface of the neck to form or reinforce a seal between the enclosure system and the neck of the fluid container. Other embodiments are described. | 2022-03-31 |
20220096326 | AUTOMATED DRUG DELIVERY DEVICE AND CONTAINER - A drug delivery system includes a drug delivery device that delivers medicament to a user and a storage container having a container body that defines at least one storage compartment. The storage container includes a controller, at least one temperature sensor associated with the at least one storage compartment, at least one temperature control device associated with the at least one storage compartment, and at least one retention mechanism coupled to the storage container. In response to a user input, the controller is adapted to activate the at least one temperature control device to adjust the temperature in the at least one storage compartment to an administration temperature and transmit a signal to the at least one retention mechanism to release the drug delivery device from the at least one storage compartment after the temperature in the at least one storage compartment reaches the administration temperature. | 2022-03-31 |
20220096327 | LIQUID TRANSFER DEVICE WITH DUAL LUMEN IV SPIKE - A liquid transfer device includes a barrel to fluidly connect to an infusion set, a vial adapter in communication with a vial adapter lumen and having a vial spike, and an intravenous (IV) spike to be sealingly inserted into an intravenous administration port of a container of an infusion liquid. The vial spike punctures a stopper of a vial containing a medicament. The IV spike has a first IV spike lumen fluidly connected to the vial adapter lumen and a second IV spike lumen fluidly connected to the infusion set. The liquid transfer device defines a first fluid path through the vial adapter lumen and the first IV spike lumen to introduce medicament from the vial to the container. The liquid transfer device also defines a second fluid path through the second IV spike lumen to pass the medicated infusion liquid from the container to the infusion set. | 2022-03-31 |
20220096328 | Apparatus and method for buffering solutions - The present invention is directed to a method an apparatus for buffering an anesthetic solution prior to an injection. The inventive apparatus employs a modified carpule which hold two solutions in fluid isolation. The buffering solution is separated from the anesthetic solution within the same carpule by way of a fluid impervious thin film. The thin film has a weakened central area which can be easily pierced by a harpoon affixed to one side of a plunger. As the plunger is advanced forward, the harpoon breaks through the thin film and causes mixing of the two solutions. | 2022-03-31 |
20220096329 | Integrated Injectable Drug Packaging and Delivery System and Methods of Use - An injection apparatus and related methods. The injection apparatus includes a housing with a proximate end and a distal end. The housing further defines a fluid pathway. A defeatable seal is fixedly positioned within the fluid pathway to separate an internal volume of the housing into a first compartment and a second compartment downstream from the first compartment. The defeatable seal is configured to fail in response to an increase in fluid pressure within the first compartment, allowing a fluid in the first compartment to pass through the second compartment and through the fluid outlet. | 2022-03-31 |
20220096330 | SMART PILL DISPENSER - A smart pill dispenser has a cylindrical interior housing portion divided into an upper storage portion, a lower control and dispensing portion, and a removable top. A cylindrical carousel with an open top and bottom has a plurality of spoke walls forming interior pill containers. A hole portion disposed through a bottom wall of the upper wall portion defines a pathway through the housing assembly. A slide assembly leads from the hole to a tray for dispensed pills. A motor coupled to a rechargeable battery and actuator assembly has a shaft coupled to an axle portion of the spoke divider and is designed to laterally rotate the spoke and axle. A computerized control system assembly is communicatively coupled to the motor assembly and a user-control assembly. The user-control assembly is disposed on an outer surface of the housing and is designed to interface with users directly or wirelessly. | 2022-03-31 |
20220096331 | CONNECTED MEDICATION DISPENSING SYSTEM - A dispensing system comprising a main body, a carousel, and a shuttle. The carousel is configured to sequentially align each of a plurality of cartridges with a dispensing outlet of the dispensing system. The shuttle is configured to sequentially align each of a plurality of compartments of each cartridge with the dispensing outlet. The dispensing system is configured to dispense a dose only after a predetermined interval of time based on a prescription. In addition, the dispensing system is connected to a network to allow the prescriber to remotely modify the prescription. The dispensing system may additionally have a biometric scanner to verify the identity of a patient, an ID scanner to authorize a pharmacist to refill the dispensing system, and a plurality of tamper sensors to alert the prescriber or the pharmacist if a patient attempts to access the dispensing system without authorization. | 2022-03-31 |
20220096332 | ANTI-REFLUX NASOGASTRIC TUBE - An anti-reflux nasogastric tube includes a tube body and a positioning sleeve. The tube body has a first end and a second end. The first end has an opening. The second end has at least one hole. The opening communicates with the at least one hole through a pipeline. The positioning sleeve is disposed at the opening and has a socket part and an outer edge. The outer edge is located at one end of the socket part. The outer diameter of the outer edge is larger than the inner diameter of the nostril of the human body. Thus, the present invention allows the anti-reflux joints to be stuck in the nasal cavity of the human body by the structure of the positioning sleeve, and does not need to adhere the tube body to the cheek of the human body by adhering, thereby reducing the patient's discomfort and increasing the aesthetic appearance and avoiding inadvertent pulling. | 2022-03-31 |
20220096333 | DRY POWDER COMPOSITIONS, METHOD OF USING THE SAME - A dry powder composition for treating hair or skin comprising crosslinked polyvinyl pyrrolidone (PVP) having an average particle size of 15 to 120 μm is disclosed. Also disclosed is the application of the dry powder composition in personal care, laundry care, home care, pet care and industrial care. | 2022-03-31 |
20220096334 | SOLID HAIR CONDITIONING COMPOSITION - The present disclosure provides a solid hair conditioning composition with a low water content. The solid hair conditioning composition of the present disclosure includes: (a) from about 10 wt % to about 70 wt % of a fatty alcohol material, (b) from about 5 wt % to about 50 wt % of a cationic surfactant, and (c) from about 0.5 wt % to about 9 wt % of a polyhydric alcohol and/or polyethylene glycol, wherein the water content is less than about 20 wt %. The present disclosure also provides a solid hair conditioner obtained from the solid hair conditioning composition. | 2022-03-31 |
20220096335 | SOLID COSMETIC COMPOSITION CONTAINING AQUEOUS SPHEROIDS DISPERSED IN A SOLID CONTINUOUS ANHYDROUS PHASE - The invention relates to a solid cosmetic composition comprising aqueous spheroids dispersed in a solid anhydrous continuous phase. The invention is also directed toward a process for preparing a solid cosmetic composition according to the invention, and also a process for making up and/or caring for bodily and/or facial skin using a solid cosmetic composition according to the invention. The invention is also directed toward a stick or a solid gel cast in a dish or a pot, and more particularly a lipstick, a foundation, and an antisun stick, comprising a cosmetic composition according to the invention. | 2022-03-31 |
20220096336 | PEPTIDE MICROPARTICLE STRUCTURE - The disclosure provides a peptide microparticle structure that can easily penetrate into the bottom layer of the skin. The peptide microparticle structure is composed, from inside to outside, of a main core, a first lipid layer, an active ingredient layer, and a second lipid layer. The main core is disposed at the center of the peptide microparticle structure, and the outer part of the main core is completely covered by the first lipid layer. The outermost layer of the peptide microparticle structure is the second lipid layer, and between the first lipid layer and the second lipid layer is the active ingredient layer. | 2022-03-31 |
20220096337 | COSMETIC COMPOSITION OF LIQUID CRYSTAL LIPID PARTICLES FOR PERSONAL CARE APPLICATIONS - The presently claimed invention relates to liquid crystal lipid particles. The presently claimed invention relates to liquid crystal lipid particles which are used in topical composition which has high moisturization efficacy, excellent skin feel, skin softness, and skin smoothness benefits. | 2022-03-31 |
20220096338 | COMPOSITIONS AND METHODS FOR STYLING HAIR - The disclosure relates to hair styling and/or shaping compositions having a unique transformative nature that allows the composition to change from a gel to a foam when a shear stress is applied to the gel. The disclosure also relates to packaging systems comprising the compositions, and methods of using the compositions. | 2022-03-31 |
20220096339 | SPRAYABLE COMPOSITIONS - The present invention relates to sprayable compositions suitable for use in topical applications, for example, as sunscreen sprays. The sprayable compositions are alcohol-based. They include active agents, as well as a particular combination of film formers. The present invention also provides a method of using the sprayable compositions, and articles of manufacture containing the sprayable compositions. | 2022-03-31 |
20220096340 | CURLING MASCARA AND METHOD OF USE - A method and mascara capable of providing semi-permanent curl to eyelashes is provided. The method involves applying a mascara that is substantially free of waxes and oxidizers to an eyelash, such as a magnetic eyelash. The mascara contains greater than 10% and less than 50% by weight of at least one ferromagnetic pigment, and between 9% and 18% solids content of a contractile polymer. After application, a magnet is temporarily held or moved over the eyelash in the direction of curl. Preferably the curling is accomplished without using a brush or eyelash tool. | 2022-03-31 |
20220096341 | Array Of Anticavity Oral Care Compositions - Arrays of anticavity oral care compositions with at least one anticavity oral care composition without fluoride. Arrays of anticavity oral care compositions with a first anticavity oral care composition comprising a first subtherapeutic anticaries drug and a second subtherapeutic drug where the first anticavity oral care composition provides a therapeutic anticaries benefit and is free of fluoride. | 2022-03-31 |
20220096342 | TITANIUM PHOSPHATE POWDER AND WHITE PIGMENT FOR COSMETIC PREPARATIONS - A titanium phosphate powder suitable as a raw material for cosmetic products and a raw material for coating materials is provided. A titanium phosphate powder according to one aspect of the present invention is a titanium phosphate powder including plate-shaped crystal particles of titanium phosphate, in which a modified layer is present on a surface of the plate-shaped crystal particles. | 2022-03-31 |
20220096343 | COSMETIC PRODUCT USING PHOTOCHROMIC POWDER AND METHOD OF MANUFACTURING THE SAME - The present invention relates to a cosmetic product using photochromic powder and a method of manufacturing the same. More particularly, the present invention relates to a cosmetic product using photochromic powder and a method of manufacturing the same, in which various formulations of cosmetic products used for the skin, lips, nails, and hair are manufactured using a photochromic powder pigment manufactured using ingredients that are harmless to the human body so that the color thereof is changed when the cosmetic products are exposed to ultraviolet light, thereby making it possible to satisfy user demand both for fun and for aesthetic improvement and to help a user create a unique style. | 2022-03-31 |
20220096344 | COSMETIC COMPOSITIONS COMPRISING 4-HYDROXYACETOPHENONE - A cosmetic composition including a water phase, the water phase comprising solubilized 4-hydroxyacetophenone with niacinamide, wherein the weight ratio of niacinamide to 4-hydroxyacetophenone in the water phase is greater than 3.0. | 2022-03-31 |
20220096345 | COSMETIC COMPOSITIONS COMPRISING AN ANTIMICROBIAL SYSTEM WITH REDUCED EYE IRRITATION OR DISCOMFORT - A cosmetic composition includes an antimicrobial system that includes an antimicrobial agent comprising 4-hydroxyacetophenone and one or more additional antimicrobial agents comprising piroctone olamine. The antimicrobial system can be used in a cosmetic composition wherein the composition is a makeup removal composition that is one of an O/W emulsion, a W/O emulsion, a micellar water, a makeup removing wipe, or a two-phase (or multi-phase) composition. The antimicrobial system may be free or essentially free of any one or more of parabens, alcohols, formaldehyde, and formaldehyde-derived compounds. In some particular embodiments, the composition is free or essentially free of parabens, formaldehyde, formaldehyde-derived compounds, pentylene glycol, phenoxyethanol, hexylglycerin, ethylhexylglycerin, octylglycerin, benzylglycerin, 3-heptoyl-2,2-propandiol, and 1,2-hexandiol. | 2022-03-31 |
20220096346 | TOPICAL COMPOSITIONS - A method of reducing oxidative damage of skin is disclosed. The method includes applying to oxidant damaged skin a topical composition comprising oligopeptide-1 and niacinamide, wherein the combination of oligopeptide-1 and niacinamide reduces oxidative damage in the skin, and wherein the oligopeptide-1 includes the sequence of caprooyl-Gly-His-Lys-Lys. | 2022-03-31 |
20220096347 | ACTIVE AGENTS FOR SKIN AND HAIR CARE WITH SENSORY MODIFYING PROPERTIES - The present invention primarily relates to the use of a fatty acid ester or of a mixture of two or more fatty acid esters or of a mixture comprising one or more fatty acid esters, wherein the fatty acid ester or one, two, three or more, preferably all, of the fatty acid ester(s) is/are selected from the group consisting of 3-hydroxypropyl caprylate, glyceryl monocaprylate, 3-hydroxypropyl undecylenate and glyceryl monoundecylenate, for modifying the sensory properties of a skin care product. The present invention further relates to methods for modifying the sensory properties of a skin care product as well as to methods for manufacturing a skin care product and to particular skin care products. | 2022-03-31 |
20220096348 | HAIR CONDITIONING COMPOSITION FOR IMPROVED DEPOSITION - A composition comprising: (i) 0.01 to 10 wt % of a linear, cationic conditioning surfactant; (ii) 0.1 to 10 wt % of a linear fatty material; (iii) a particulate benefit agent; (iv) 0.01 to 5 wt %, at 100% active, of a branched cationic co-surfactant, as defined by structure (1) wherein: —R | 2022-03-31 |
20220096349 | COSMETIC COMPOUNDING AGENT, COSMETIC AND PRODUCTION METHOD THEREOF - Provided are a novel cosmetic compounding agent capable of imparting superior properties such as a water and moisture retention property to a cosmetic for use on the hair and skin; a cosmetic using the cosmetic compounding agent; and a method for producing the cosmetic. The cosmetic compounding agent of the present invention contains an organic ammonium salt having a hydrogen-bonding functional group(s) in a cation and/or an anion. | 2022-03-31 |
20220096350 | OLIGONUCLEOTIDES FOR SKIN CARE - Provided are small activating nucleic acid molecules for skin care and uses thereof. The small activating nucleic acid molecule of the present invention comprises two oligonucleotide strands of 16 to 35 nucleotides in length, wherein one nucleotide strand has at least 75% homology or complementarity to a target selected from a promoter region of a target gene. Also provided are skin care products comprising a small activating nucleic acid molecule targeting the promoter region of the AQP3, AQP9, ELN, COL1A1, COL1A2, COL3A1, HAS1, HAS2, HAS3 or MFAP2 genes or a nucleic acid encoding the same and optionally an carrier or other effective ingredients. Further provided are methods for upregulating the expression of a target gene in cells using the small activating nucleic acid molecule or the nucleic acid encoding the same and improving skin conditions using the skin care products. | 2022-03-31 |
20220096351 | ORAL COMPOSITION - An oral composition for treating diseases in the mouth caused by formulation of biofilms on teeth. The oral composition includes water, stannous ion source, casein phosphopeptide-amorphous calcium phosphate, and at least citric acid or a citric acid salt. | 2022-03-31 |
20220096352 | HUMAN PLACENTAL COLLAGEN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal. | 2022-03-31 |
20220096353 | REDUCED-COST COSMETIC FORMULATIONS THAT REDUCE VISIBLE SIGNS OF AGEING - The present invention discloses a number of formulations (including some that comprise Lunasin and reduce the visible signs of ageing by reducing skin wrinkles) that can be used as body-wash and related skin and hair treatments that can be manufactured using high quality ingredients at a reasonable cost, lower than comparable available products. | 2022-03-31 |
20220096354 | PREPARATION METHOD AND USE OF ARTIFICIAL EXOSOME COMPLEX - A preparation method and use of an artificial exosome complex are provided. Raw materials for preparing the artificial exosome complex include linear polyethyleneimine (PEI) and hyaluronic acid (HA). The linear PEI can be obtained through the HA-PEI preparation process of the present disclosure, and most PEI is branched currently. According to the HA-PEI preparation method, HA-PEI with a specific molecular weight can be quantitatively prepared. The preparation process involves controllable operation steps, and thus can be used for large-scale industrial production. The prepared HA-PEI can promote the absorption of an encapsulated active substance by deep skin cells through the ligand activity of HA and the membrane permeability of linear PEI. | 2022-03-31 |
20220096355 | FRAGRANCE COMPOSITIONS - The various aspects presented herein relate to the field of perfumery. In particular, the present disclosure provides compositions having an increased and/or improved long-lastingness and/or fragrance profile. In addition, the present disclosure provides methods of using such compositions to increase and/or improve the long-lastingness and/or fragrance profile of a fragrance composition. | 2022-03-31 |
20220096356 | SYSTEM AND METHOD FOR PRIMING EYE COSMETICS - Cosmetic compositions, and methods of use, where the cosmetic compositions are multi-purpose oil-in-water emulsions that contain (i) a surfactant system of high HLB surfactants and (ii) a high load of talc. The emulsions are capable of being used as a base for eye cosmetics, in order to enhance wear of eyeshadow and removal of mascara. | 2022-03-31 |
20220096357 | HYDRATING NO-RINSE COMPOSITION FOR MAKEUP REMOVAL - A makeup removal composition includes at least one of each of a silicone-based emulsifier, a branched, liquid alkane, an emollient ester, ether, or carbonate, a hydrating agent, and water. In some embodiments, the composition may further include one or more additives including preservatives, actives, and fragrances. | 2022-03-31 |
20220096358 | HAIR CARE SYSTEM, HAIR CARE METHOD AND USE OF A HAIR CARE SYSTEM - The present application relates to a hair care system comprising a shampoo composition (A) and a conditioner composition (B), and optionally a mask composition (C). The invention is also related to a hair care method and the use of a hair care system. | 2022-03-31 |
20220096359 | BUTTER PREPARATION PROCESS - The present invention relates to a butter comprising a vegetable oil and said hydrogenated vegetable oil. | 2022-03-31 |
20220096360 | SERUMS FOR REDUCING LIPID PEROXIDATION - Cosmetic compositions comprising high amount of | 2022-03-31 |
20220096361 | METHOD FOR OBTAINING AN EXTRACT OF PATCHOULI LEAVES AND COSMETIC USES THEREOF - The invention relates to a method for obtaining an extract of patchouli leaves comprising a supercritical carbon dioxide extraction and a co-solvent such as ethanol. The invention also relates to a patchouli extract obtainable by the method of the invention, a composition comprising such an extract, and the cosmetic use of a composition according to the invention for care of the skin, the scalp and the appendages. | 2022-03-31 |
20220096362 | Aqueous Compositions Comprising Hops-Metal Complex - Hops-metal complex. Aqueous compositions that include hops-metal complex. Aqueous compositions that include hops beta acid-tin and/or hops beta acid-zinc complex. Aqueous compositions that include lupulone-tin and/or lupulone-zinc complex. | 2022-03-31 |
20220096363 | Oral Care Composition Comprising Hops And Flavor - Oral care compositions including hops and up to about 0.20% of aromatic ester flavor. Oral care compositions including hops and up to about 0.20% of methyl salicylate. Fluoride-free toothpaste compositions including hops and up to about 0.20% of methyl salicylate. Fluoride-free toothpaste compositions including hops and less than about 0.20% of methyl salicylate. | 2022-03-31 |
20220096364 | Oral Care Compositions Comprising Prenylated Flavonoid - Oral care compositions that include prenylated flavonoid and metal ion. Oral care compositions that include prenylated flavonoid and calcium. Anticavity oral care compositions that comprise prenylated flavonoid. Anticavity oral care compositions that comprise prenylated flavonoid and are free of fluoride. Oral care compositions including metal ion, such as stannous chloride, and prenylated flavonoid, such as xanthohumol. | 2022-03-31 |
20220096365 | NATURAL SKIN CARE SOLUTION - Compositions for body, skin, and haircare are disclosed herein. In a non-limiting embodiment, a method for making a composition may include combining baking soda with arrowroot powder to create a dry mixture, and adding coconut oil to the dry mixture. The method may further include combining the dry mixture with at least one of emu oil, jojoba oil, and vitamin E, and then combining the heated coconut oil and the dry mixture for a predetermined amount of time to create a viscous mixture. The method may also include heating an amount of beeswax to a predetermined temperature, emulsifying the viscous mixture in the beeswax, and then reducing the temperature of the beeswax to room temperature to create a soft, yet substantially solid composition. | 2022-03-31 |
20220096366 | PROGRAMMABLE PHARMACEUTICAL COMPOSITIONS FOR CHRONO DRUG RELEASE - The present disclosure provides programmable osmotic-controlled oral compositions providing delayed release of a therapeutically acceptable amount of a drug. In certain embodiments, the programmable osmotic-controlled compositions of the disclosure provide a lag time that is independent of the presence or absence of food, type of food, pH, gastric emptying, and volume of gastric fluid. The programmable osmotic-controlled oral compositions of the disclosure comprise a multilayer core comprising a drug for controlled release, wherein the core is coated with a semipermeable membrane comprising an orifice and, optionally, an immediate release coating, comprising a drug for immediate release, over the semipermeable membrane. The multilayered core comprises a pull layer containing the drug and a push layer. The pull layer comprises at least two layers: a placebo layer for providing a desired lag time for the drug release; and an active layer containing the drug and providing a delayed controlled release of the drug. The compositions of the disclosure can be programmed to provide a desired and precise lag time, and release drug, after the lag time, at a rhythm, e.g., that matches the human circadian rhythm of a condition's symptoms and/or of the individual being treated in the application of the therapy to optimize therapeutic outcome and minimize side effects. | 2022-03-31 |
20220096367 | ORAL THIN FILM - The present invention additionally relates to a dosage form for an active substance, selected from the group of cannabinoids, for dissolving in the oral cavity, comprising a first film layer and a second film layer, arranged over the first film layer, wherein the composition of the first film layer can be identical to that of the second film layer and comprises a water soluble polymer, the first and second film layer being connected to each other via the overlapping edges thereof, forming at least one cavity, and the cavity being filled with an active substance selected from the group of cannabinoids. | 2022-03-31 |
20220096368 | METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE - Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided. | 2022-03-31 |
20220096369 | COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF - The present disclosure is related to transdermal cannabinoid compositions and methods of use thereof. | 2022-03-31 |
20220096370 | HIGH PENETRATION COMPOSITION AND USES THEREOF - The present invention relates to compositions and uses of novel high penetration compositions or high penetration prodrugs (HPP), in particular HPPs for 4-aminophenol derivatives, which are capable of crossing biological barriers with high penetration efficiency. The HPPs herein are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, due to the ability of penetrating biological barriers, the HPPs herein are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs herein can be administered to a subject through various administration routes. For example, the HPPs can be locally delivered to an action site of a condition with a high concentration due to their ability of penetrating biological barriers and thus obviate the need for a systematic administration. For another example, the HPPs herein can be systematically administer to a biological subject and enter the general circulation with a faster rate. | 2022-03-31 |
20220096371 | BIODEGRADABLE MICRONEEDLE SYSTEM WITH SUSTAINED RELEASE - A transdermal, biodegradable microneedle system and method for treating pain in a patient. The transdermal easy-to-use biodegradable microneedle system can be fully embedded into the skin to perform a sustained and nearly zero-order release kinetics of therapeutics over a long period of time (at least 30 days) for the treatment of pain. | 2022-03-31 |
20220096372 | Trans-Tympanic Membrane Delivery Platform and Uses Thereof - Provided herein are methods and composition for trans-tympanic membrane delivery of therapeutic agents such as antimicrobial agents, anti-inflammatory agents, and anti-biofilm agents to the middle ear for rapid, localized treatment and prevention of diseases and conditions associated with a middle ear infection. In particular, provided herein are cationic, anionic, and polymer-based nanoparticles that provide a platform for delivery of therapeutic cargo, as well as cationic, anionic, and polymer-based nanoparticles compositions for rapid, localized delivery of therapeutic agents to the middle ear. | 2022-03-31 |
20220096373 | Bandage Contact Lens for Sustained Drug Delivery - A drug-loaded, flexible and transparent composite material for use in bandages and bandage contact lenses to topically administer a medication in a sustained and effective way is described, as well as methods of fabrication and use thereof. The composite material comprises drug carrying porous nanoparticles embedded within a transparent, flexible polymeric matrix and, when applied as a bandage, provides topical drug delivery to a tissue, while protecting it from the environment, yet allowing facile examination due to transparency. | 2022-03-31 |
20220096374 | METHOD AND COMPOSITION FOR MAKING AN ORAL SOLUBLE FILM, CONTAINING AT LEAST ONE ACTIVE AGENT - A method of making an oral soluble film, containing at least one active agent, includes providing a well of a predetermined size; depositing a film forming composition in the well; depositing an active agent composition in the well, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming an admixture in the well; and drying the admixture in the well. Alternatively, the method includes providing a well of a predetermined size; depositing a film forming composition including at least one active agent in the well, the film forming composition having a viscosity below 2000 centipoise; and drying the film forming composition in the well. | 2022-03-31 |
20220096375 | STABILIZED NON-ENVELOPED VIRUS COMPOSITIONS - The present invention relates to methods and compositions of thermostable nonenveloped virus as obtained by a laminar counter-current spray drying process. The compositions comprise aerosolizable amorphous particles, comprising free, non-encapsulated nonenveloped virus and an excipient, wherein the particles typically have a mass median aerodynamic diameter (MMAD) of less 5 μm and comprise less than 5% water. | 2022-03-31 |
20220096376 | DRUG DELIVERY PLATFORM USING W/O/W-TYPE TRIOLEIN EMULSION PROMOTIVE OF BLOOD-BRAIN BARRIER OPENING - The present invention relates to a composition for drug delivery to a tissue having a tight junction comprising a triolein emulsion of an internal water phase/oil phase/external water phase (Water/Oil/Water, W/O/W) structure in which oil droplet comprises triolein and water droplets are enclosed in the oil droplet, as an active ingredient, and a method of preparing the same, and the triolein emulsion of the W/O/W-type structure according to the present invention has excellent safety because it retains the BBB opening activity of triolein as it is and the water droplets are enclosed in the oil droplets and contain surfactants and can further enclose fat-soluble drugs in the oil droplets and thus it can more effectively deliver drugs to tissues having tight junctions such as the brain, testicles, and retina. | 2022-03-31 |
20220096377 | TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF - Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension. | 2022-03-31 |
20220096378 | TOPIRAMATE ORAL LIQUID SUSPENSION AND USE THEREOF - Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension. | 2022-03-31 |
20220096379 | SELF-EMULSIFYING DRUG FORMULATION FOR IMPROVING MEMBRANE PERMEABILITY OF COMPOUND - An objective of the present invention is to provide lymphatically-transported self-emulsifying formulations for enhancing membrane permeability of poorly membrane-permeable compounds in oral administration of the compounds. It was discovered that by applying lymphatically-transported self-emulsifying formulations containing a surfactant containing oleic acid as a moiety or oily component to poorly membrane-permeable compounds containing a cyclic peptide and having features (i) and (ii) below, the membrane permeability and absorbability of the compounds can be improved: (i) log D (pH 7.4) value of the compounds is 3.2 or greater; and (ii) Caco-2 Papp (cm/sec) value of the compounds is 1.8E-6 or less. | 2022-03-31 |
20220096380 | ORAL FORMULATIONS OF A BIOLOGICALLY ACTIVE PEPTIDE AND USES THEREOF - Oral formulations comprising a biologically active peptide, such as an apel in peptide, wherein the peptide is encapsulated in particles comprising phospholipids such as 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and a poloxamer are provided. Said nanoparticles may be embedded in a carbohydrate matrix comprising a polysaccharide such as pectin, and a cross-linking agent such as calcium chloride. The nanoparticle formulation may further comprise a polyethylene glycol (PEG) and/or cholesterol. Also provided are methods of making said formulations, oral dosage forms comprising the same, and methods of treating or preventing diseases using said formulations. | 2022-03-31 |
20220096381 | LIPID COMPOSITION - An object of the present invention is to provide a lipid composition making it possible to achieve excellent delivery of nucleic acids. According to the present invention, there is provided a lipid composition containing a lipid represented by Formula (1) or a salt thereof, a nonionic lipid, a lipid having a nonionic hydrophilic polymer structure, and a nucleic acid, in which the lipid composition contains or does not contain a zwitterionic lipid, and in a case where (A) represents a molar ratio in percentage of the lipid represented by Formula (1) or a salt thereof to total lipids constituting the lipid composition and (B) represents a molar ratio in percentage of the zwitterionic lipid to total lipids constituting the lipid composition, (A) and (B) satisfy 40<(A)−(B)≤90. | 2022-03-31 |
20220096382 | POLYMERSOMES FUNCTIONALISED WITH MULTIPLE LIGANDS - The present invention is directed to a nanoparticle or microparticle for binding to the surface of a cell, wherein the nanoparticle or microparticle comprises (i) multiple different ligand types on its external surface which are capable of binding to different respective receptor types on said cell surface, and (ii) a polymer brush on its external surface. The present invention is further directed to pharmaceutical compositions comprising a plurality of nanoparticles or microparticles of the invention, medical uses of such nanoparticles or microparticles, and a vaccine comprising such nanoparticles or microparticles. | 2022-03-31 |
20220096383 | LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER - The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c including histidine, trehalose and lysine. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital. | 2022-03-31 |
20220096384 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES - Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form. | 2022-03-31 |
20220096385 | ORODISPERSIBLE DOSAGE UNIT CONTAINING AN ESTETROL COMPONENT - The invention provides an orodispersible solid pharmaceutical dosage unit having a weight between 30 and 1,000 mg, said dosage unit consisting of: 0.1-25 wt. % of estetrol particles containing at least 80 wt. % of an estetrol component selected from estetrol, estetrol esters and combinations thereof; and 75-99.9 wt. % of one or more pharmaceutically acceptable ingredients; the solid dosage unit comprising at least 100 μg of the estetrol component; and wherein the solid dosage unit can be obtained by a process comprising wet granulation of estetrol particles having a volume weighted average particle size of 2 μm to 50 μm. The solid dosage unit is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration. | 2022-03-31 |
20220096386 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE - Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release. | 2022-03-31 |
20220096387 | SUBLINGUAL DELIVERY FOR MITIGATION OF SIDE EFFECTS ASSOCIATED WITH LURASIDONE - Sublingual delivery vehicles (SDVs) including tablets and gel strips may mitigate or eliminate side effects associated with active ingredients included in the SDVs. An exemplary SDV may include: an ingredient mixture including a flavoring agent and a lubricant; and a specified dose of lurasidone, wherein the SDV dissolves within thirty seconds of sublingual administration. A method of manufacturing an SDV may include mixing a set of ingredients, wherein the set of ingredients includes: a flavoring agent, a lubricant, and a specified dose of lurasidone; and forming the SDV from the mixed set of ingredients. A method for treating mental disorders may include administering, once a day, an ingredient mixture including: a flavoring agent; a lubricant; and a specified dose of lurasidone, wherein the ingredient mixture is administered via a sublingual delivery vehicle (SDV). | 2022-03-31 |
20220096388 | APPARATUS AND PROCESS FOR SECONDARY ENCAPSULATION OF SOLID INCLUSIONS USING THE ROTARY DIE PROCESS - Disclosed herein are a manufacturing process for encapsulating at least one solid inclusion into a softgel capsule. Also disclosed herein is a system for secondary encapsulation of solid inclusions using the rotary die process and system. Also disclosed herein are dosage forms having at least one solid inclusion encapsulated therein. | 2022-03-31 |
20220096389 | PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS SOLID DISPERSIONS AND METHODS OF PREPARATION THEREOF - Provided are amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material. | 2022-03-31 |
20220096390 | SILICA MODIFIED VATERITE JANUS DRUG DELIVERY PARTICLES - Silica modified vaterite Janus nanoparticles are provided, together with methods for the synthesis of such particles. The disclosed methods make use of a Pickering emulsion, in a scalable aqueous process. The silica-modified surface is amenable to chemical modification, for example with physiologically acceptable labels. | 2022-03-31 |
20220096391 | UNIDIRECTIONAL PRESENTATION OF MEMBRANE PROTEINS IN NANOPARTICLE-SUPPORTED LIPOSOMES - Presentation of membrane proteins to host immune systems has been a challenging problem due to complexity arising from the poor in vivo stability of the membrane-mimetic media often used for solubilizing the membrane proteins. The Inventors report the use of functionalized, biocompatible nanoparticles as substrates to guide the formation of proteoliposomes that can present many copies of membrane proteins in a unidirectional manner. The approach was demonstrated to present the membrane-proximal region of the HIV-1 envelope glycoprotein. These nanoparticle-supported liposomes are broadly applicable as membrane antigen vehicles for inducing host immune responses. In some instances, the technology supports generation of antibodies that do not generate an immunogenic response in comparison to conventional protein presentation (i.e., liposome). | 2022-03-31 |
20220096392 | EDDS CHELATED NANOCERIA WITH CATALASE-LIKE ACTIVITY - A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, ethylenediaminedisuccinic acid, an oxidant, water, and optionally citric acid, is provided along with temperature conditions to directly form within the reaction mixture, a stable dispersion of cerium oxide nanoparticles. Biocompatible nanoparticles comprised of cerium oxide, ethylenediaminedisuccinic acid, and optionally citric acid, are described. An increase in catalase-like enzyme activity is demonstrated by cerium oxide nanoparticles prepared with citric acid and ethylenediaminedisuccinic acid. | 2022-03-31 |
20220096393 | TRANSDERMAL SYSTEM WITH OVERPLASTER AND RING SYSTEM - The invention relates to a system containing: a transdermal therapeutic system (TTS); a cylindrical separating layer having an outer periphery and an inner periphery; and a backing layer, which is applied to the cylindrical separating layer and protrudes beyond the cylindrical separating layer over the entire periphery. The invention further relates to a system for improving the adhesion of a TTS, to the use of the system, and to a kit containing the system. | 2022-03-31 |
20220096394 | Medical Use of Honokiol - The invention involves the pharmaceutical use of honokiol, in particular the use of honokiol in inhibiting medulloblastoma, and it has been experimentally proved that honokiol can inhibit the proliferation and induce cell cycle arrest and apoptosis of medulloblastoma cells; promoting hair growth, and it has been experimentally proved that honokiol can promote hair growth and has no toxic and side effects on liver and kidney; and promoting white hair blackening, and it has been experimentally proved that honokiol can promote white hair blackening and has no toxic side effects on liver and kidney. | 2022-03-31 |
20220096395 | CANNABIDIOL AND/OR DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASES - The invention relates to the use of cannabidiol (CBD) and/or a derivative thereof, in the treatment of mitochondrial diseases. In certain preferred embodiments, the CBD, and/or a derivative thereof is substantially devoid of tetrahydrocannabinol (THC). Moreover, the present invention also relates to a composition comprising the CBD and/or a derivative thereof and to a method of treating mitochondrial diseases in a subject, comprising administering to the subject in need thereof a therapeutically effective amount of the CBD, a derivative thereof and/or a composition comprising thereof. | 2022-03-31 |
20220096396 | TREATMENT OF AUTISM WITH CANNABIDIOL - The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject. | 2022-03-31 |
20220096397 | PARENTERAL FORMULATIONS - The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations. Preferably the parenteral containing formulation comprises a cannabinoid; an isotonic agent; a surfactant; and one or more stability enhancers. Furthermore the cannabinoid may be selected from one or more of cannabichromene (CBC), cannabichromenic acid (CBCV), cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigerol propyl variant (CBGV), cannabicyclol (CBL), cannabinol (CBN), cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV) and tetrahydrocannabivarinic acid (THCVA). | 2022-03-31 |
20220096398 | COMPLEXES AND COMPOSITIONS COMPRISING PROBUCOL AND USES THEREOF - The present invention relates to complexes comprising probucol or derivatives thereof and mesoporous silica, methods for producing such complexes and uses thereof. The present invention also relates to uses of the complexes in the treatment of inflammation- and oxidation-related diseases and disorders. | 2022-03-31 |
20220096399 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 - The invention provides methods and compositions for treatment of a subject with a solid tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject has failed at least one prior chemotherapeutic regimen. | 2022-03-31 |
20220096400 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 IN COMBINATION WITH IMMUNE CHECKPOINT MODULATORS - Presented herein are methods for the treatment of oncological disorders by the co-administration of Coenzyme Q10 and immune checkpoint modulators. The Coenzyme Q10 formulations may be at least one of intravenous, topical, or by inhalation. Co-administration of the Coenzyme Q10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy. | 2022-03-31 |
20220096401 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA - Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) a non myorelaxing hypnotic and/or 5-HT2A inverse agonist or antagonist. | 2022-03-31 |
20220096402 | ANTIBIOFILM FORMULATIONS - Methods and compositions related to molecules and formulations comprising antibiofilm materials are provide, including new formulations of Deep Eutectic Solvents (DES) that are chemically related to choline geranate. Specifically, geranic acid (a component of choline geranate DES) is a molecule from the isoprenoid/terpene family of compounds. Other members of this family as DES components include isoprenoid acids and chemical derivatives thereof. | 2022-03-31 |
20220096403 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING DIABETIC CATARACT - The present disclosure relates to a pharmaceutical composition for treating or preventing diabetic cataract, which contains midodrine or a pharmaceutically acceptable salt thereof as an active ingredient. | 2022-03-31 |
20220096404 | CHEMICALLY AND PHYSICALLY STABLE TOPICAL OPHTHALMIC NEPAFENAC-BASED FORMULATIONS - Topical ophthalmic Nepafenac-based formulations, which are particularly stable from both chemical and physical points of view, are provided. | 2022-03-31 |
20220096405 | Combination Therapy for Metastatic Cancer - The present invention relates to methods and sets of drugs for the effective treatment of metastatic cancer and the administration of a set of drugs that overcome mechanisms of resistance to DNA-damaging agents, thereby sensitizing cancer cells to said DNA-damaging agents. The methods involve the administration of a set of drugs comprising melphalan, BCNU, hydroxocobalamin, and ascorbic acid. In a preferred embodiment, ethanol is also added to the set of drugs and bone marrow toxicity is reversed with an infusion of bone marrow stem cells. The methods also involve the depletion of GSH in tumors and the selective delivery of drugs to solid tumors. The methods also involve preventing the loss of catalase function and preventing oxidant-induced hemolysis and/or methemoglobin formation in subjects treated with oxidant drugs or agents that generate hydrogen peroxide, wherein said methods comprise the systemic administration of ethanol. | 2022-03-31 |
20220096406 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS IN A PARTICULAR POPULATION - Disclosed herein are methods for treating, ameliorating, and/or preventing Alzheimer's Disease in a specific patient population using tramiprosate, valyl-3-amino-1-propanesulfonic acid, or a pharmaceutically acceptable salt thereof based upon a combination of APOE4 status and disease severity. | 2022-03-31 |
20220096407 | COMPOSITION FOR INHIBITING RESPIRATORY VIRUSES AND RESPIRATORY VIRUS PREVENTION AND TREATMENT METHOD - A composition inhibits respiratory viruses and a method prevents and treats a respiratory. Respiratory viral infections are extremely common clinically, but the current therapeutic drugs for viral infections still cannot meet the treatment needs. An inhalant inhibits respiratory viruses and adopts a method of inhaling high-temperature acetic acid steam for prevention and treatment. Acetic acid in the high-temperature steam can release hydrogen ions to inactivate viruses in the respiratory tract, so as to prevent the onset of the disease and provide a therapeutic effect. In addition, the composition can be used to inhibit fungi and bacteria in vitro and prevent skin diseases and respiratory diseases caused by bacteria and fungi. The prevention and treatment method is easy to implement and has low costs and important clinical application value. | 2022-03-31 |
20220096408 | COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA AND OTHER CONDITIONS - Embodiments of the instant disclosure relate to novel compositions and methods for treating a subject having homocystinuria. In some embodiments, compositions and methods disclosed herein concern improving efficacy of betaine to reduce dietary compliance requirements and improve outcomes. In accordance with these embodiments, a subject having or suspected of developing homocystinuria can be treated with formate, a salt thereof, a formate derivative or formate precursor or prodrug agent alone or in combination with trimethylglycine or other HCU treatments. In other embodiments, a subject having or suspected of developing homocystinuria can be treated with zinc and/or trimethylglycine and/or formate derivative to treat homocystinuria in the subject. In other embodiments, a subject having or suspected of developing Nonketotic hyperglycinemia (NKH) can be treated with formate, a salt thereof, a formate derivative, or formate precursor or prodrug agent to treat NKH in the subject. | 2022-03-31 |
20220096410 | PHARMACEUTICAL COMPOSITION FOR INTRAOCULAR OR ORAL ADMINISTRATION FOR TREATMENT OF RETINAL DISEASES - The present invention may provide a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatment, the composition comprising an effective amount of one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method therefor, a group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine and indapamide. | 2022-03-31 |
20220096411 | COMBINING METABOLIC STIMULATION AND AMINO ACIDS TO SENSITIZE TOLERANT BACTERIA TO ANTIBIOTICS - The present disclosure provides compositions and methods capable of potentiating the effects of antibiotics against bacterial infections that either have developed, or that possess the potential to develop, antibiotic tolerance. Methods of sensitizing antibiotic tolerant bacteria to antibiotics, as well as pharmaceutical compositions and therapeutic/prophylactic methods directed at antibiotic tolerant bacteria are also provided. | 2022-03-31 |
20220096412 | Combination Drug Substance of Polyamine Transport Inhibitor and DFMO - Provided herein are combinations comprising difluoromethylornithine (DFMO), or an ionic form thereof, and a compound of the following structural formula: | 2022-03-31 |
20220096413 | METHOD OF USING COMPOSITION FOR TREATMENT OF VEISALGIA - A method for the treatment of veisalgia with a composition. The composition comprises at least one sugar compound, mineral salts, at least one compound for cell protection, at least one compound for promoting cell function, at least one compound for promoting detoxification, at least one neurotransmitter, at least one trace element, folic acid, optionally further trace elements and optionally a stimulating alkaloid. The composition contains no analgesic. A dosage of the composition, a therapy kit and an analgesic are also disclosed. | 2022-03-31 |
20220096414 | LEVOTHYROXINE LIQUID FORMULATIONS - The present invention is directed to a pharmaceutical product which includes a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes a cyclodextrin, water, and an amine, and has a pH above the buffering range of the amine. The liquid formulation of the invention is stable and ready-to-use. | 2022-03-31 |
20220096415 | Composition for Improving Cognitive Function - The purpose of the present invention is to provide a composition comprising conjugated linoleic acid for improving a cognitive function in an animal and to provide a composition for improving a cognitive function, comprising, as an active ingredient, c9,c11-conjugated linoleic acid (c9,t11-CLA)-containing conjugated linoleic acid (CLA) or a glyceride thereof. | 2022-03-31 |
20220096416 | FELINE FOOD COMPOSITION - Nutritionally complete feline food compositions comprising EPA/DHA and carbohydrates are disclosed herein. These nutritionally complete feline food compositions can be used in dry or wet food composition. The compositions can be used to for preventing and/or treating cardiac hypertrophy in feline animals, such as cats. | 2022-03-31 |
20220096417 | INDUCTION OF ARTERIOGENESIS WITH AN NO (NITRIC OXIDE) DONOR - The present invention inter alia relates to a method of promoting collateral circulation comprising the step of exposing a subject to a therapeutically effective amount of an NO donor wherein the therapeutically effective amount of the NO donor promotes arteriogenesis sufficient to augment collateral circulation in a physiological or pathological condition. | 2022-03-31 |
20220096418 | KETONE BODY PRODUCTION PROMOTING COMPOSITION - The present invention provides a ketone body production promoting composition comprising: as an active ingredient, a fatty acid glyceride which contains one to three molecules of fatty acids as constituent fatty acids and is a C6 or less fatty acid glyceride in which at least one molecule of the constituent fatty acids is a saturated fatty acid having 6 or less carbon atoms. | 2022-03-31 |
20220096419 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES - The present invention provides compounds of formula (I), and pharmaceutical compositions thereof. | 2022-03-31 |
20220096420 | Acetylcholinesterase Inhibitors for Treatment of Dermatological Conditions - Embodiments of the invention involve treating skin afflictions by the topical or oral use of acetylcholinesterase inhibitor. By effectively reducing or eliminating the population of | 2022-03-31 |
20220096421 | Active Ingredient, Pharmaceutical Composition, and Medicinal Product for HIV and AIDS Therapy - This invention relates to the active ingredient of a pharmaceutical composition consisting of micronized monoclinic symmetry crystals (MMSCs) of sodium {[4-({[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl] acetyl}amino)-3-chlorophenyl]-sulfonyl}(propanoyl)azanide with an average particle diameter ≤130 μm and methods of use thereof in the treatment of Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS). | 2022-03-31 |
20220096422 | BLOOD-BRAIN BARRIER PERMEABILITY REGULATOR AND USE THEREOF - The present invention relates to use of SC79 or an analogue thereof in the preparation of a blood-brain barrier permeability regulator. The blood-brain barrier permeability regulator comprises SC79 or an analogue thereof as an active ingredient, which down-regulates expression of tight junction proteins Claudin-5 and Occludin by activating Claudin-5 and Occludin signaling pathway downstream the protein kinase B, and thereby increases the blood-brain barrier permeability, and enhances the efficiency of transportation of a brain targeting drug delivery system, especially, an Angiopep-2-modified glycolipid nano-delivery system, into the brain. The present invention also relates to a kit comprising the blood-brain barrier permeability regulator and a brain targeting drug delivery system. According to the present invention, use of the blood-brain barrier permeability regulator in combination with a brain targeting drug delivery system can enhance the efficiency of transportation of a brain targeting drug delivery system into the brain, and thereby improve the therapeutic efficacy of the brain targeting drug delivery system. | 2022-03-31 |
20220096423 | Treatment of Bladder Cancer by Local Administration of Taxane Particles - Disclosed herein are methods for treating and inhibiting the recurrence of bladder cancer by local administration of compositions comprising taxane particles such as docetaxel particles. Administration methods include intratumoral injection, direct injection into surgical tumor resection sites, and intravesical instillation. | 2022-03-31 |